A Study of LY3437943 in Participants With Type 2 Diabetes

NCT04867785 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the experimental drug LY3437943 in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 281 people

Who can join Ages 18–75 · all sexes

Timeline Started 2021-05 · est. completion 2022-10

Where 43 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT04867785 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.

Treatments tested

LY3437943 Drug

Administered SC
Dulaglutide Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04867785 ↗